<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The BCL-2 overexpression is a hallmark of follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (FL) </plain></SENT>
<SENT sid="1" pm="."><plain>Since patients with FL often suffer from resistant to chemotherapy refractory disease, the development of new regimens is required </plain></SENT>
<SENT sid="2" pm="."><plain>Herein, we analyze for the first time the effects of a B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> 2 (Bcl-2) <z:chebi fb="68" ids="48706">antagonist</z:chebi>, HA14-1, alone and in combination with <z:chebi fb="0" ids="35610">antineoplastic agents</z:chebi> commonly used against follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, in human FL cell lines with t(14;18) </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> cell lines tested were sensitive to HA14-1-induced cytotoxicity and <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, as depicted by morphological changes, SYTO16/PI staining, oligonucleosomal DNA fragmentation and loss of Deltapsi(m) </plain></SENT>
<SENT sid="4" pm="."><plain>Moreover, HA14-1 significantly enhanced <z:chebi fb="0" ids="41879">dexamethasone</z:chebi>- and <z:chebi fb="0" ids="28748">doxorubicin</z:chebi>-mediated (in schedule independent and dependent manner, respectively), but not <z:chebi fb="0" ids="28445">vincristine</z:chebi>-mediated cytotoxicity and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
</text></document>